ITM-11 significantly improved PFS and OS compared to everolimus in GEP-NET patients, meeting primary and secondary endpoints. Subgroup analyses showed ITM-11's efficacy across tumor grades and prior ...

Eligible patients were randomly assigned 1:1 to receive ribociclib at 400 mg per day via a 3-weeks-on, 1-week-off dosing schedule for 3 years in combination with a nonsteroidal AI for at least 5 years ...

AstraZeneca (NASDAQ:AZN) and partner Daiichi Sankyo (OTCPK:DSKYF) (OTCPK:DSNKY) on Saturday announced data from two ...

BERLIN -- Almost half of patients with advanced ALK -positive non-small cell lung cancer (NSCLC) have lived 7 years or longer ...

Objectives To investigate the occurrence of depression and mental health disorders other than depression among Brazilian people with intellectual disabilities, analysing data from a national household ...

Research shows that more daytime movement in pregnant women with hyperglycemia can raise nighttime blood sugar, highlighting ...

The addition of tiragolumab to Tecentriq and Avastin did not significantly improve progression-free survival in ...

Patients with PD-L1-positive metastatic triple-negative breast cancer reported improved emotional function and pain with sacituzumab govitecan plus pembrolizumab compared with chemotherapy plus ...

Chronic malaria exposure has been proposed to modulate immune function, but its long-term effects on antibody-mediated responses to unrelated pathogens remain poorly defined. Whether these effects ...

Phase 3 study presentations in SLE to show efficacy results across multiple clinical endpoints, including low disease activity/remission, flares, fatigue, joint pain and quality of lifePresentation of ...